Clinical Trials
3 trialsNCT02032810 2023-01-20
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03982134 2019-10-04
PDR001 + Panobinostat for Melanoma and NSCLC
University of Iowa
Phase 1 Withdrawn
NCT01065467 2017-03-28
Panobinostat (LBH589) in Patients With Metastatic Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed